Related Experiment Videos
What next for rheumatoid arthritis therapy?
Simon M Blake1, Barbara A Swift
1Department of Musculoskeletal Diseases, GlaxoSmithKline Pharmaceuticals, 1250 S Collegeville Road, Collegeville, PA 19426, USA. simon.m.blake@gsk.com
Current Opinion in Pharmacology
|May 14, 2004
Summary
Biological agents offer rheumatoid arthritis treatment but aren't universally effective or accessible. Research now focuses on new targets and affordable oral small molecules to improve therapy for all patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory joint disease.
- Biological agents have improved RA treatment, targeting symptoms and disease progression.
- Limitations include variable efficacy, high cost, and administration route.
Purpose of the Study:
- To explore novel therapeutic targets for RA.
- To identify affordable, orally active small molecule alternatives to biological agents.
Main Methods:
- This study focuses on the ongoing search for new RA treatments.
- Methods involve identifying unmet needs in current biological therapies.
Main Results:
- Current biological agents show limitations in efficacy and accessibility.
- There is a clear need for alternative treatment strategies.
Conclusions:
- Continued research is essential for developing new RA therapies.
- Focus is on identifying novel targets and oral small molecules for broader patient access.